Morgan Stanley reduced its position in Amedisys Inc (NASDAQ:AMED) by 49.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 85,445 shares of the health services provider’s stock after selling 82,508 shares during the period. Morgan Stanley’s holdings in Amedisys were worth $4,366,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of AMED. American Century Companies Inc. increased its stake in shares of Amedisys by 148.7% in the first quarter. American Century Companies Inc. now owns 1,200,754 shares of the health services provider’s stock worth $61,347,000 after buying an additional 717,939 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Amedisys by 125.0% in the first quarter. Bank of New York Mellon Corp now owns 781,256 shares of the health services provider’s stock worth $39,915,000 after buying an additional 433,956 shares during the period. Norges Bank acquired a new stake in shares of Amedisys during the fourth quarter worth about $13,483,000. Monarch Partners Asset Management LLC acquired a new stake in shares of Amedisys during the first quarter worth about $8,984,000. Finally, FMR LLC increased its stake in shares of Amedisys by 6.9% in the first quarter. FMR LLC now owns 2,352,632 shares of the health services provider’s stock worth $120,196,000 after buying an additional 152,632 shares during the period. Institutional investors own 99.80% of the company’s stock.

Amedisys Inc (AMED) traded up 1.35% during midday trading on Friday, reaching $48.88. The company’s stock had a trading volume of 352,034 shares. The firm has a market cap of $1.66 billion, a P/E ratio of 41.78 and a beta of 0.89. The firm has a 50 day moving average price of $56.08 and a 200 day moving average price of $54.19. Amedisys Inc has a one year low of $34.58 and a one year high of $65.91.

Amedisys (NASDAQ:AMED) last released its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 EPS for the quarter, beating the consensus estimate of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The business had revenue of $378.80 million during the quarter, compared to the consensus estimate of $380.80 million. During the same quarter in the prior year, the firm earned $0.42 EPS. The business’s revenue was up 5.0% on a year-over-year basis. Equities research analysts forecast that Amedisys Inc will post $2.21 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/amedisys-inc-amed-stake-lowered-by-morgan-stanley/1478972.html.

AMED has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $57.00 price objective on shares of Amedisys in a research report on Friday, April 28th. Mizuho upgraded Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective on the stock in a research report on Wednesday, May 3rd. Royal Bank Of Canada reiterated a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a research report on Monday, June 5th. Finally, Stephens increased their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 4th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $56.50.

In related news, Director Bruce D. Perkins acquired 500 shares of the company’s stock in a transaction on Thursday, May 25th. The stock was acquired at an average price of $59.69 per share, with a total value of $29,845.00. Following the acquisition, the director now directly owns 13,331 shares of the company’s stock, valued at $795,727.39. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David B. Pearce sold 1,000 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the transaction, the insider now directly owns 10,488 shares of the company’s stock, valued at approximately $524,400. The disclosure for this sale can be found here. 2.80% of the stock is owned by corporate insiders.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.